Method of treatment using papillomavirus L2 protein
US6380157B1 · kind B1 · utility
3Cited by
2References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | Apr 30, 2002 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The L2 protein of papillomavirus (particularly BPV-2 and BPV-4) has been cloned as a fusion protein with beta-galactosidase and GST; both as the whole protein and as fragments. Vaccination of calves is found to have both a prophylactic effect in tumour prevention and a therapeutic effect in tumour regression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.